MEGF10: A Protein with Potential as A Drug Target Or Biomarker

Target Name: MEGF10

NCBI ID: G84466

MEGF10

MEGF10: A Protein with Potential as A Drug Target Or Biomarker

MEGF10, also known as MEGF10 variant 3, is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the extracellular matrix (ECM) protein family, which plays a critical role in the structure and function of tissues and organs.

One of the unique features of MEGF10 is its ability to interact with a variety of different proteins, including those involved in cell signaling and signaling pathways. This interaction between MEGF10 and other proteins has led to its potential as a drug target or biomarker.

MEGF10 has been shown to play a role in a number of different processes in the body, including the regulation of cell growth, differentiation, and survival. It has also been shown to be involved in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the potential drug-targeting potential of MEGF10 is its ability to interact with a variety of different proteins, including those involved in cell signaling and signaling pathways. This interaction between MEGF10 and other proteins has led to its potential as a therapeutic agent for a variety of different conditions.

For example, MEGF10 has been shown to play a role in the development and progression of cancer. Studies have shown that high levels of MEGF10 are associated with the development of a variety of different types of cancer, including breast, ovarian, and prostate cancer. Additionally, research has suggested that inhibiting the activity of MEGF10 may be a potential therapeutic approach for cancer treatment.

MEGF10 has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that individuals with certain genetic mutations, which are thought to cause these conditions, have lower levels of MEGF10 compared to individuals without the mutations. Additionally, research has suggested that increasing the levels of MEGF10 in individuals with these conditions may contribute to the progression of the disease.

MEGF10 has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that individuals with these conditions have lower levels of MEGF10 compared to individuals without the conditions. Additionally, research has suggested that decreasing the levels of MEGF10 in individuals with these conditions may be a potential therapeutic approach for treating these disorders.

In addition to its potential as a drug target or biomarker, MEGF10 is also of interest as a potential therapeutic agent for a variety of other conditions. For example, it has been shown to play a role in the regulation of cell migration and has been shown to be involved in the development and progression of a variety of diseases, including neurodegenerative diseases and autoimmune disorders.

Overall, while the potential drug-targeting and biomarker potential of MEGF10 is still being explored, it is clear that this protein has the potential to contribute to a variety of different therapeutic approaches for a wide range of conditions. Further research is needed to fully understand the role of MEGF10 in these processes and to develop safe and effective drugs or other therapeutic agents that can target this protein.

Protein Name: Multiple EGF Like Domains 10

Functions: Membrane receptor involved in phagocytosis by macrophages and astrocytes of apoptotic cells. Receptor for C1q, an eat-me signal, that binds phosphatidylserine expressed on the surface of apoptotic cells (PubMed:27170117). Cooperates with ABCA1 within the process of engulfment. Promotes the formation of large intracellular vacuoles and may be responsible for the uptake of amyloid-beta peptides (PubMed:20828568, PubMed:17643423). Necessary for astrocyte-dependent apoptotic neuron clearance in the developing cerebellum (PubMed:27170117). Plays role in muscle cell proliferation, adhesion and motility. Is also an essential factor in the regulation of myogenesis. Controls the balance between skeletal muscle satellite cells proliferation and differentiation through regulation of the notch signaling pathway (PubMed:28498977, Ref.14). May also function in the mosaic spacing of specific neuron subtypes in the retina through homotypic retinal neuron repulsion. Mosaics provide a mechanism to distribute each cell type evenly across the retina, ensuring that all parts of the visual field have access to a full set of processing elements (PubMed:17498693, PubMed:17643423, PubMed:20828568, PubMed:22101682, PubMed:27170117, PubMed:28498977)

The "MEGF10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEGF10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets